Clinical trials: Advanced Fibrosis
Hepatocellular Carcinoma, Liver Cancer
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer
This is a non-randomized, open-label, single-institution phase I/II therapeutic trial of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT01264705
- Testing
- bavituximab (0.3 mg/kg) and sorafenib, bavituximab (1.0 mg/kg ) and sorafenib, bavituximab (3.0 mg/kg) and sorafenib
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- University of Texas Southwestern Medical Center
Psychiatric Disorder, Psychiatric Hospitalization
Advanced Chronic Liver Disease Screening by Transient Elstography in Patients Hospitalised in a Psychiatric Unit
Scares data exists concerning the prevalence of chronic liver diseases in people with psychiatric disorders. There are still many barriers to screening and linkage to care for patients having somatic illness.
- Conditions
- Psychiatric Disorder, Psychiatric Hospitalization, Advanced Chronic Liver Disease, Liver Fibrosis
- Trial name
- HEPSY (NCT05602870)
- Testing
- non invasive evaluation of liver fibrosis by transient elastography (Fibroscan ®)
- Where
- France
- Volunteers
- 180 people
- Sponsor
- University Hospital, Montpellier
Chronic Hepatitis C
Efficacy of Long-term Ribavirin in Non-responders With Chronic Hepatitis C and Advanced Fibrosis
The rate of sustained virological response to a course of standard antiviral therapy (peg-interferon plus ribavirin) of patients with chronic hepatitis C infected by genotype 1 with advanced fibrosis (>F2) is rather low.
- Trial name
- RIBACIR (NCT00840489)
- Testing
- Ribavirin, Colchicine
- Where
- 3 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Hospital Universitario Ramon y Cajal
HCC, Liver Cirrhosis
Open Label Trial of Immunotherapy for Advanced Liver Cancer
The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.
- Trial name
- HCC (NCT02256514)
- Testing
- Daily oral dose of hepcortespenlisimut-L
- Where
- Mongolia
- Volunteers
- 120 people
- Sponsor
- Immunitor LLC
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue
Obesity and type 2 Diabetes Mellitus prevalence has doubled in the last 30 years and nearly one fifth of UAE population has Type 2 Diabetes while more than quarter has obesity.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Type 2 Diabetes, Liver Fat
- Trial name
- NCT05751720
- Testing
- GIP/GLP-1a
- Where
- United Arab Emirates
- Volunteers
- 30 people
- Sponsor
- Dr Adnan Agha
Non-alcoholic Fatty Liver Disease, Liver Fibrosis
Early Detection of Advanced Fatty Liver Disease
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the western world, affecting one in every three subjects.
- Trial name
- NCT03608748
- Where
- Israel
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- HaEmek Medical Center, Israel
Hepatitis C
Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)
This is a non-randomized, open-label study of a fixed dose combination (FDC) of elbasvir (50 mg) and grazoprevir (100 mg) (EBR/GZR or MK-5172A) in participants with chronic hepatitis C virus (HCV) genotype 1 (GT1) infection with…
- Trial name
- NCT03143998
- Testing
- MK-5172A
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Varices, Non-alcoholic Fatty Liver
Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
Non-alcoholic fatty liver disease (NAFLD) is defined as accumulation of fat in the liver which is not related to either alcohol excess or other causes such viral infection, immune-mediated, or medication related which can lead to…
- Conditions
- Esophageal Varices, Non-alcoholic Fatty Liver, Compensated Cirrhosis
- Trial name
- NCT05485714
- Testing
- Reviewing records retrospectively of patients undergoing screening endoscopy
- Where
- United Arab Emirates
- Volunteers
- 73 people
- Sponsor
- United Arab Emirates University
Hepatitis C
Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel
Primary objective: 1. To estimate the effectiveness of treatment with FDC of Zepatier with or without ribavirin in Israeli patients with CHC and advanced fibrosis in real life setting. Secondary objective: 1.
- Trial name
- NCT03144440
- Volunteers
- 200 people
- Sponsor
- Carmel Medical Center
Esophageal Cancer, Radiation Pneumonitis
Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology
Although recent global trends indicate reduced postoperative mortality after esophagectomy, major morbidity, in particular pulmonary, remains high, with considerable health and economic costs.
- Conditions
- Esophageal Cancer, Radiation Pneumonitis, Pulmonary Fibrosis, Respiratory Failure
- Trial name
- NCT03462524
- Testing
- Esophagectomy
- Where
- 2 sites in Ireland
- Volunteers
- 384 people
- Sponsor
- St. James's Hospital, Ireland
Heart Failure, Transplant; Failure, Heart
Shear Wave Elastography
In individuals needing a left ventricular assist device (LVAD), right heart failure (RHF) is a serious complication post-surgery, associated with worsened outcomes including mortality.
- Conditions
- Heart Failure, Transplant; Failure, Heart, Decompensated Heart Failure, Fibrosis, Liver
- Trial name
- NCT04493346
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Baylor Research Institute
Cystic Fibrosis
Lung Transplant READY CF 2: A Multi-site RCT
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant.
- Trial name
- NCT06030206
- Testing
- Investigator-designed lung transplant education resource (Research Intervention), Publicly available transplant education resource (Attention-control)
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- University of Washington
Cystic Fibrosis, Advanced Lung Disease
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
The purpose of this study is to evaluate the safety and tolerability of LUM/IVA combination therapy in subjects 12 years and older with CF and advanced lung disease and who are homozygous for the F508del CFTR mutation
- Trial name
- NCT02390219
- Testing
- Lumacaftor, Ivacaftor
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
Spleen Stiffness Measurement for the Detection of Advanced Fibrosis
Measurement of spleen stiffness (SSM) has shown potential as a complementary tool to liver stiffness measurement (LSM) for the assessment of portal hypertension in patients with MASLD, particularly in the setting of compensated…
- Trial name
- S-MASH (NCT07440511)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
End Stage Liver DIsease, Cirrhosis, Liver
Use of EL-FIT App to Promote Physical Activity
Transplant-eligible patients with cirrhosis and ESLD, age 40-70, MELD >/= 10 referred to transplant physical therapy will be invited to participate.
- Trial name
- EL-FIT (NCT04604860)
- Testing
- Fitness intervention
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Pittsburgh
Advanced Chronic Liver Disease, Urinary Infection
The INFECIR-2 Albumin Prevention Study
The aim of this study is to evaluate whether albumin administration improves short-term survival in patients with advanced cirrhosis and bacterial infections other than Spontaneous Bacterial Peritonitis (SBP).
- Conditions
- Advanced Chronic Liver Disease, Urinary Infection, Pneumonia, Cholangitis
- Trial name
- INFECIR2 (NCT02034279)
- Testing
- Albumin
- Where
- Spain
- Volunteers
- 136 people
- Sponsor
- EASL - CLIF Consortium
Liver Fibrosis, Alcohol Abuse
Efficacy of Simvastatin in Alcoholic Liver Fibrosis
Evaluate the efficacy of simvastatin in reducing liver fibrosis in patients with advanced fibrosis due to alcohol
- Trial name
- SIMFIB (NCT04971577)
- Testing
- Simvastatin 40mg
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Anna Cruceta
Hepatopulmonary Syndrome
Pilot Study of Pentoxifylline for Hepatopulmonary Syndrome
The Hepatopulmonary syndrome (HPS) results from intrapulmonary microvascular dilatation that impairs arterial oxygenation in the setting of cirrhosis or portal hypertension.
- Trial name
- NCT00593658
- Testing
- pentoxifylline
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Alabama at Birmingham
Cystic Fibrosis (CF), CFTR-related Disorders
A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis
Sometimes it is very difficult to tell if someone has cystic fibrosis (CF), especially when they have rare CF genes. Without this certainty, they are unlikely to get the correct treatment so their health may be affected.
- Trial name
- ADVANCE-CFTR (NCT07402434)
- Testing
- Rectal Biopsy, Rectal biopsy taken opportunistically during endoscopy procedure for other reasons., Blood test for CFTR Genotyping
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Royal Brompton & Harefield NHS Foundation Trust
Chronic Hepatitis C, Chronic Liver Disease
Long Term Follow-up of Hepatitis C Cured Patients
Objectives: The general objective of the present project is to gain a better understanding of disease outcome in cACLD patients treated with the new oral DAA.
- Conditions
- Chronic Hepatitis C, Chronic Liver Disease, Cirrhosis
- Trial name
- NCT03246048
- Volunteers
- 300 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute